Gene edited therapies (Apellis Pharmaceuticals/Beam Therapeutics)

N/A

Report date: 2025/10/28 17:00:21

Base Information

Drug NameGene edited therapies (Apellis Pharmaceuticals/Beam Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > LipidCell and gene therapy > Gene therapy > Gene editing > Base editing
Mechanisms of ActionComplement C3 modulators
TargetsComplement C3
Therapy Area/IndicationsComplement-Mediated Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesApellis Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesBeam Therapeutics IncApellis Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsComplement-Mediated Diseases
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A